Oxurion NV
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991… Read more
Oxurion NV (OXUR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.097x
Based on the latest financial reports, Oxurion NV (OXUR) has a cash flow conversion efficiency ratio of 0.097x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.16 Million) by net assets (€-11.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oxurion NV - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Oxurion NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Oxurion NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oxurion NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fonterra Shareholders Fund
AU:FSF
|
0.038x |
|
COMM HEALTH SYSTEMS (CG5.SG)
STU:CG5
|
-0.053x |
|
CC JAP.+GROWTH TR. LS-01
F:8EH
|
N/A |
|
Mountain Top Properties Inc
PINK:MTPP
|
0.000x |
|
7Fit SA
WAR:7FT
|
N/A |
|
SThree plc
LSE:STEM
|
0.183x |
|
Varengold Bank AG
F:VG8
|
N/A |
|
LEGAL & GENERAL (LGI.SG)
STU:LGI
|
N/A |
Annual Cash Flow Conversion Efficiency for Oxurion NV (2006–2024)
The table below shows the annual cash flow conversion efficiency of Oxurion NV from 2006 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-11.06 Million | €-2.07 Million | 0.187x | -74.75% |
| 2023-12-31 | €-13.19 Million | €-9.77 Million | 0.741x | -83.04% |
| 2022-12-31 | €-4.58 Million | €-20.02 Million | 4.367x | -82.18% |
| 2021-12-31 | €-1.11 Million | €-27.16 Million | 24.508x | +2365.49% |
| 2020-12-31 | €25.05 Million | €-27.10 Million | -1.082x | -85.42% |
| 2019-12-31 | €53.31 Million | €-31.10 Million | -0.583x | -97.46% |
| 2018-12-31 | €105.31 Million | €-31.12 Million | -0.295x | -249.85% |
| 2017-12-31 | €133.36 Million | €26.30 Million | 0.197x | +206.66% |
| 2016-12-31 | €109.86 Million | €-20.31 Million | -0.185x | -13.08% |
| 2015-12-31 | €170.01 Million | €-27.79 Million | -0.163x | +27.00% |
| 2014-12-31 | €208.01 Million | €-46.58 Million | -0.224x | -325.38% |
| 2013-12-31 | €258.77 Million | €25.71 Million | 0.099x | -18.50% |
| 2012-12-31 | €227.97 Million | €27.79 Million | 0.122x | +173.54% |
| 2011-12-31 | €118.03 Million | €-19.56 Million | -0.166x | -36.00% |
| 2010-12-31 | €138.19 Million | €-16.84 Million | -0.122x | +5.59% |
| 2009-12-31 | €93.72 Million | €-12.10 Million | -0.129x | -167.36% |
| 2008-12-31 | €62.39 Million | €11.96 Million | 0.192x | +162.73% |
| 2007-12-31 | €48.44 Million | €-14.80 Million | -0.306x | -28.03% |
| 2006-12-31 | €35.28 Million | €-8.42 Million | -0.239x | -- |